Beta-agarase mutant and application thereof
By truncating the amino acid sequence of β-agarase YM01-3, the β-agarase mutant Y3R1 was constructed, which solved the problem of insufficient thermal stability and achieved higher thermal stability and catalytic activity, making it suitable for the industrial production of agar oligosaccharides.
Patent Information
- Application Number
- CN202411257565.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-22
AI Technical Summary
The existing β-agarase has poor thermal stability, which cannot meet the needs of industrial production and limits the development and utilization of agar resources.
By truncating the amino acid sequence of β-agarase YM01-3, a β-agarase mutant Y3R1 was constructed, which improved its thermal stability and catalytic activity.
The optimal reaction temperature of mutant Y3R1 was increased to 65℃, and the residual activity at 60℃ and 70℃ was increased by 41.9% and 20.9%, respectively, and the maximum reaction rate was doubled.
Smart Images

Figure BDA0005034545030000031 
Figure BDA0005034545030000032 
Figure BDA0005034545030000042
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and specifically relates to a beta-agarase mutant and application thereof. Background Art
[0002] Agar is used as a thickener and gelling agent in the food industry, and its added value is relatively low. Agar oligosaccharides degraded from agar have a variety of beneficial biological activities, including anti-inflammatory, antioxidant, probiotic, antibacterial and skin whitening, which makes agar oligosaccharides have application potential in food, medicine, agriculture and other fields, increasing the high-value utilization of agar and greatly improving the economic benefits of agar. So far, there are two commonly used methods for preparing agar oligosaccharides, chemical method and enzymatic method. The acid hydrolysis method commonly used in the chemical method is difficult to control in the process of producing agar oligosaccharides, and some non-target products will be produced, which require further separation and purification. The enzymatic method is considered to be the preferred method for sustainable commercial production of agar oligosaccharides because it can specifically hydrolyze agar and does not form harmful compounds.
[0003] Since agar has the characteristics of thermoreversible gelation, the viscosity of its solution will increase with the decrease of temperature. Therefore, in the industrial enzymatic hydrolysis of agar, in order to make the substrate and enzyme fully contact and avoid the reaction solution from being too viscous or gelling, the temperature of the reaction solution is generally strictly controlled; and in the extreme environment of industrial production, the enzyme needs to have excellent thermal stability, catalytic activity and other characteristics. Most agarases from natural sources have poor thermal stability and cannot meet the needs of industrial production, limiting the development and utilization of agar resources.
[0004] β-Agarase YM01-3 is a T Among the 15 agarases, β-agarase has the strongest agarase degradation activity, with an optimum temperature of 60°C, and the main enzymatic hydrolysis products are neoagarotetrose and neoagarotehose. However, the thermal stability of the enzyme needs to be improved. The enzyme activity drops sharply after incubation at 60°C for 1 hour, leaving less than 30% residual activity, which greatly limits its application and promotion. Therefore, reasonable improvement of β-agarase and optimization of the thermal stability of the enzyme make β-agarase have good application prospects in the industrial production of hydrolyzing agar under high temperature conditions. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems in the above-mentioned technology to a certain extent. To this end, the present invention provides a β-agarase mutant and its application, wherein the optimal reaction temperature, thermal stability and catalytic activity of the mutant are improved.
[0006] To this end, in the first aspect of the present invention, a β-agarase mutant is provided, wherein the β-agarase mutant is obtained by truncating the amino acids of the agarase with an amino acid sequence as shown in SEQ ID NO: 1, and the amino acid sequence of the β-agarase mutant is shown in SEQ ID NO: 2.
[0007] According to a β-agarase mutant of the present invention, the β-agarase mutant is derived from Streptomyces agarophilus YM01 with an amino acid sequence as shown in SEQ ID NO: 1. T The wild-type β-agarase YM01-3 with a full length of 420 amino acids was truncated to the mutant Y3R1 containing 313 amino acids through primer design; the thermal stability and catalytic activity of the mutant were synergistically improved; compared with the wild-type β-agarase YM01-3 (WT), the optimal reaction temperature of the mutant Y3R1 was 65℃, which was 5℃ higher than that of WT; the residual activity of the mutant Y3R1 was increased by 41.9% and 20.9% after treatment at 60℃ and 70℃ for 1h; the V max The value is 5000U / mg, and the V max The maximum reaction rate of mutant Y3R1 was improved to 10000U / mg.
[0008] In a second aspect of the present invention, a gene encoding the above-mentioned β-agarase mutant is provided, and the nucleotide sequence of the gene is shown in SEQ ID NO:3.
[0009] In the third aspect of the present invention, a construct is provided, which comprises a gene encoding the above-mentioned β-agarase mutant.
[0010] In a fourth aspect of the present invention, a recombinant cell expressing the above-mentioned β-agarase mutant, or containing the above-mentioned gene, or containing the above-mentioned construct is provided.
[0011] In the fifth aspect of the present invention, there is provided the use of the above-mentioned β-agarase mutant, or the above-mentioned encoding gene, or the above-mentioned construct, or the above-mentioned recombinant cell in degrading agar or preparing agar oligosaccharides.
[0012] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is an agarose gel electrophoresis analysis of the truncated mutant gene of β-agarase according to an embodiment of the present invention, wherein M: Marker; 1-3: Y3R1 engineering strain; 4-6: YM01-3 engineering strain;
[0014] Figure 2 This is the SDS-PAGE analysis of the truncated mutant of β-agarase according to the embodiment of the present invention, wherein, M: Marker; 1: YM01-3 engineering strain; 2: Y3R1 engineering strain;
[0015] Figure 3 Analysis of the enzyme activity of the truncated mutant of β-agarase according to an embodiment of the present invention;
[0016] Figure 4 is the optimal reaction temperature of the truncated mutant of β-agarase according to the embodiment of the present invention;
[0017] Figure 5 is the optimal reaction pH of the truncated mutant of β-agarase according to the embodiment of the present invention, wherein (A) is YM01-3, and (B) is Y3R1;
[0018] Figure 6 is the thermal stability of the truncated mutant of β-agarase according to the embodiment of the present invention;
[0019] Figure 7 1 and 2 are the kinetic parameters of the truncated mutants of β-agarase according to the examples of the present invention, wherein (A) is YM01-3 and (B) is Y3R1. DETAILED DESCRIPTION
[0020] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.
[0021] The disclosure below provides many different embodiments or examples to realize different implementations of the present invention. In order to simplify the disclosure of the present invention, specific embodiments or examples are described below. Of course, they are only examples, and the purpose is not to limit the present invention. In addition, the examples of various specific processes and materials provided by the present invention, those of ordinary skill in the art can be aware of the applicability of other processes and / or the use of other materials. Unless otherwise stated, the implementation of the present invention will adopt the traditional techniques in the fields of chemistry, molecular biology, etc. within the capabilities of those skilled in the art. In addition, unless otherwise stated, in this article, nucleic acids are written from left to right in the direction of 5' to 3', and amino acid sequences are written from left to right in the direction of amino terminal to carboxyl terminal.
[0022] The present invention is described below by means of illustrative specific examples, which are not intended to limit the scope of the present invention in any way. It is particularly noted that the reagents used in the present invention are commercially available unless otherwise specified.
[0023] Example 1 Construction of truncated mutants of β-agarase
[0024] Using the recombinant plasmid pET-28a(+) / YM01-3 containing the wild-type enzyme gene fragment (encoded by the sequence shown in KF413621.1) as a template, restriction sites BamH I and Xho I were added at the 5' and 3' ends, respectively, and primers were designed on the primer design website (https: / / crm.vazyme.com / cetool / simple.html). According to the CD-Search analysis on the NCBI website, two truncated bodies Y3R1 and Y3GH were constructed. The truncated body primers are shown in Table 1.
[0025] Table 1 Truncated enzyme primers
[0026]
[0027] (1) Using the recombinant plasmid pET-28a(+) / YM01-3 containing the wild-type enzyme gene fragment as a template, the target plasmid was amplified using PCR technology. The amplification reaction system and reaction conditions are as follows, wherein the specific upstream and downstream primers were purchased from Borui Biotechnology Co., Ltd. Plasmid extraction was performed according to the instructions of the bacterial plasmid mini-extraction kit of TianGen. Using the recombinant plasmid as a template, the Y3R1 gene was amplified using PCR.
[0028] Table 2 Amplification reaction system
[0029]
[0030]
[0031] Table 3 Amplification reaction conditions
[0032]
[0033] The target gene fragment was recovered according to the instructions of the DNA purification kit of TianGen Company and stored at -20°C.
[0034] (2) Double restriction enzyme digestion reaction of target gene and expression plasmid. The reaction conditions are as follows: the reagents are mixed, centrifuged briefly, and reacted at 37°C for 1 h. After the double restriction enzyme digestion reaction, the DNA fragments are recovered using a DNA purification kit and the concentration of the recovered products is measured using an ELISA reader. The reaction system is shown in Table 4.
[0035] Table 4 Double enzyme digestion reaction system
[0036]
[0037] (3) Ligation reaction. The reaction conditions are as follows: after the reagents are mixed, centrifuge briefly and react at 16°C for 40 min; after the ligation reaction, use a DNA purification kit to recover the DNA fragments, then use 1% agarose gel electrophoresis to detect the target gene band, and use an enzyme reader to determine the concentration of the recovered product. The reaction system is shown in Table 5.
[0038] Table 5 Ligation reaction system
[0039]
[0040] (4) Conversion reaction:
[0041] Thaw E.coli DH5α or E.coli BL21 (DE3) competent cells on ice. Add 20μL of ligation product to 100μL competent cells and let stand on ice for 30 minutes. Heat shock in a water bath at 42°C for 90 seconds, and immediately place on ice to cool for 2-3 minutes. Add 900μL LB liquid culture medium (without kanamycin) and shake the bacteria at 37°C for 60 minutes. Centrifuge at 3000-3500rpm for 3 minutes. Remove 800μL of supernatant and resuspend the bacteria with a pipette. Use a sterile spreading stick to spread the bacterial solution on an LB solid culture medium plate (containing 50μg / mL of kanamycin sulfate). Place the plate in a 37°C constant temperature incubator and invert for 12-16 hours.
[0042] (5) Identification of positive transformants:
[0043] A single colony cultured overnight was picked and placed in 10 mL LB liquid medium (containing kanamycin sulfate) for expansion culture for 12-16 hours. PCR was performed on the bacterial solution. The PCR reaction system and reaction conditions are shown in Tables 6 and 7. The size of the PCR product was detected by 1% agarose gel electrophoresis. The results are shown in Figure 1 As shown, the gene fragment size of the β-agarase truncated mutant Y3R1 is between 1000 bp and 750 bp, which is consistent with the theoretical value of 939 bp. The bacterial solution was sent to Xiamen Borui Biotechnology Co., Ltd. for sequencing identification, and the sequencing results were analyzed using DNAMAN 9.0 software. The sequencing results showed that the target sequence of the inserted gene was consistent with the theoretical sequence.
[0044] Table 6 Amplification reaction system
[0045]
[0046] Table 7 Amplification reaction conditions
[0047]
[0048] Example 2 Heterologous Expression of β-Agarase Truncated Mutant Gene in E. coli BL21
[0049] The recombinant plasmid containing the mutant enzyme gene (prepared in Example 1) was extracted with reference to the instructions of the bacterial plasmid mini-extraction kit of TIANGEN Company, and the plasmid was transformed into E. coli BL21 competent cells, and the cells were spread on LB culture plates (containing 50 μg / mL kanamycin) and cultured at 37°C for 18 hours. A single colony on the above LB plate was selected and inoculated into 5 mL LB liquid culture medium (containing 50 μg / mL kanamycin), and after overnight culture at 37°C and 180 rpm, colony PCR was used to verify the positive transformants. The reaction system and reaction conditions are shown in Tables 8 and 9, respectively.
[0050] Table 8 Colony PCR reaction system
[0051]
[0052] Table 9 Colony PCR reaction conditions
[0053]
[0054] Induced expression of truncated mutants of β-agarase: Inoculate E. coli BL21 containing mutant enzyme gene into 50 mL LB liquid medium and culture at 37°C and 180 rpm for 18 h. Transfer the bacterial solution to 300 mL LB liquid medium at a 1% inoculation volume and continue to shake and culture at 37°C until the bacterial OD reaches 0. 600 Between 1.0 and 1.2. Add 30 μL IPTG (0.5 mol / L) to the bacterial solution and culture at 16°C and 180 rpm for 24 h.
[0055] Purification and analysis of truncated mutants of β-agarase by affinity chromatography: Purify the recombinant protein according to the Ni-NTA instruction manual of Qiagen. Add glycerol to the purified sample to 20%, mix well, and store at -20°C. Determine the protein concentration by Bradford method. Take an appropriate amount of sample for SDS-PAGE electrophoresis analysis. The results are as follows: Figure 2 In the figure, M, protein molecular weight standard; 1, purified YM01-3 protein; 2, purified Y3R1 protein; the molecular weight of the β-agarase truncated mutant sample band is between 34-43 kDa, and the purified Y3R1 protein is consistent with the theoretical protein molecular weight of 34.1 kDa.
[0056] Example 3 Enzyme properties study
[0057] Activity determination of β-agarase: The activity of β-agarase was determined using the 3,5-dinitrosalicylic acid method (DNS method). Take 5 μL of enzyme solution (enzyme content is 200 ng) and add 495 μL of 5 mg / mL agarose substrate solution (dissolved in 50 mmol / L sodium phosphate buffer, pH 7.0). After incubation at 60°C for 15 minutes, add 500 μL of DNS colorimetric agent, boil for 10 minutes, and use a microplate reader to determine the absorbance at 540 nm. The activity unit of agarase is defined as: under certain conditions, the amount of enzyme required to generate 1 μmoL galactose per minute is one enzyme activity unit (U). The experiment was repeated three times and the average value was taken. Figure 3 As shown, the enzyme activity of the β-agarase truncation mutant measured at 60°C was increased by 5.18% compared with the wild-type β-agarase YM01-3.
[0058] Determination of the optimum temperature of the enzyme: Using 5 mg / mL agarose solution (dissolved in 50 mmol / L sodium phosphate buffer, pH 7.0) as the substrate, the catalytic activity of β-agarase (enzyme content of 200 ng) at different temperatures (50-75°C) was studied, and the optimum temperature was explored with the highest enzyme activity as 100%. Figure 4 As shown, the optimal reaction temperature of WT is 60°C, while the optimal reaction temperature of the β-agarase truncation mutant Y3R1 is 65°C, which is 5°C higher than that of WT.
[0059] Determination of the optimal pH of the enzyme: The catalytic activity of β-agarase (enzyme content of 200 ng) on agarose substrate in different pH buffers (pH 3.0-11.0) was determined at 60°C. The optimal reaction pH of the enzyme was studied with the highest enzyme activity as 100%. The buffers used were 50 mmol / L citric acid-Na2HPO4 buffer (pH 3.0-5.0), sodium phosphate buffer (pH 5.0-9.0), and Gly-NaOH buffer (pH 9.0-11.0). The results are shown in Table 1. Figure 5 As shown, the optimal reaction pH of WT and β-agarase truncation mutant Y3R1 was 7, indicating that truncation did not change the optimal reaction pH of Y3R1.
[0060] Analysis of enzyme thermal stability: β-agarase (enzyme content 400ng) was incubated at different temperatures (50, 55, 60, 65 and 70℃) for 60min, placed on ice for 5min, and then 5mg / mL agarose substrate (dissolved in 50mmol / L sodium phosphate buffer, pH 7.0) was added to react for 15min. The residual activity of β-agarase was measured with the enzyme activity without heat treatment as 100% to study its thermal stability. Figure 6As shown in the figure, WT had only 11.7% residual activity after incubation at 60°C for 1h, and almost no activity at 70°C. The β-agarase truncation mutant Y3R1 showed high thermal stability at different temperatures. Compared with WT, the β-agarase truncation mutant Y3R1 increased the residual activity by 41.9% at 60°C and 20.9% at 70°C, indicating that the thermal stability of the β-agarase truncation mutant Y3R1 was improved compared with WT.
[0061] Determination of enzyme kinetic parameters: 0.1%-0.3% agarose substrate solution was incubated with purified β-agarase at 60°C and pH 7.0 for 15 min. The Michaelis constant (K) of β-agarase was calculated using the Lineweaver-Burk double reciprocal plot method. m ) and the maximum enzyme reaction rate (V max ). The result is Figure 7 As shown, after calculation, the K of WT m and V max The values were 7.5 mg / mL and 5000 U / mg, respectively. The K m and V max 18.0 mg / mL and 10000 U / mg, respectively. Compared with WT, the K m The value increased, indicating that the substrate binding affinity decreased after truncation; in addition, the maximum reaction rate of the β-agarase truncation mutant Y3R1 was doubled.
[0062] In summary, according to an embodiment of the present invention, the amino acid sequence as shown in SEQ ID NO: 1 is derived from Streptomyces agarophilus YM01 T The wild-type β-agarase YM01-3 with a full length of 420 amino acids was truncated to a β-agarase truncated mutant Y3R1 containing 313 amino acids through primer design; compared with the wild-type β-agarase YM01-3 (WT), the optimal reaction temperature of the β-agarase truncated mutant Y3R1 was 65°C, which was 5°C higher than that of WT. The residual activity of Y3R1 increased by 41.9% and 20.9% after treatment at 60°C and 70°C for 1h. The V max The value is 5000U / mg, and the V max The maximum reaction rate of Y3R1 was improved to 10000U / mg.
[0063] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.
[0064] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A β-agarase mutant, characterized in that The β-agarase mutant is obtained by truncating the amino acids of the agarase with the amino acid sequence shown in SEQ ID NO:
1. The amino acid sequence of the β-agarase mutant is shown in SEQ ID NO:
2.
2. A gene encoding the β-agarase mutant according to claim 1, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO:
3.
3. A construct, characterized in that Comprising the gene as claimed in claim 2.
4. A recombinant cell expressing the β-agarase mutant according to claim 1, or containing the gene according to claim 2, or containing the construct according to claim 3.
5. The recombinant cell according to claim 4, characterized in that The recombinant cell uses Escherichia coli BL21 (DE3) as a host cell.
6. Use of the β-agarase mutant according to claim 1, or the encoding gene according to claim 2, or the construct according to claim 3, or the recombinant cell according to claim 4 or 5 in degrading agar or preparing agar oligosaccharides.
